General Information of Drug Transporter (DT)
DT ID DTD0104 Transporter Info
Gene Name SLC16A13
Transporter Name Monocarboxylate transporter 13
Gene ID
201232
UniProt ID
Q7RTY0
Post-Translational Modification of This DT
Overview of SLC16A13 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Phosphorylation X-Ubiquitination X: Amino Acid

Phosphorylation

  Serine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A13 [1]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

350

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A13 Serine 350 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC16A13 [1]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

360

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A13 Serine 360 has the potential to affect its expression or activity.

  Tyrosine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A13 [1]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

339

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A13 Tyrosine 339 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC16A13 [1]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

362

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC16A13 Tyrosine 362 has the potential to affect its expression or activity.

Ubiquitination

  Lysine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC16A13 [2]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

415

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC16A13 Lysine 415 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLC16A13 [3] , [4]

Role of PTM

Potential impacts

Modified Residue

Lysine

Modified Location

420

Experimental Method

Co-Immunoprecipitation

Detailed Description

Ubiquitination at SLC16A13 Lysine 420 has the potential to affect its expression or activity.
References
1 Characterization of native protein complexes and protein isoform variation using size-fractionation-based quantitative proteomics. Mol Cell Proteomics. 2013 Dec;12(12):3851-73.
2 Systematic functional prioritization of protein posttranslational modifications. Cell. 2012 Jul 20;150(2):413-25.
3 UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol. 2018 Jul;25(7):631-640.
4 Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells. Proteomics. 2018 Aug;18(15):e1700388.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.